Should I buy or sell Ocular Therapeutix stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares. View OCUL analyst ratings or view top-rated stocks .

What is Ocular Therapeutix's stock price target for 2024?

5 brokers have issued 12-month target prices for Ocular Therapeutix's stock. Their OCUL share price targets range from $12.00 to $24.00. On average, they expect the company's share price to reach $16.80 in the next year. This suggests a possible upside of 167.1% from the stock's current price. View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts .

How have OCUL shares performed in 2024?

Ocular Therapeutix's stock was trading at $4.46 at the start of the year. Since then, OCUL shares have increased by 41.0% and is now trading at $6.29. View the best growth stocks for 2024 here .

Are investors shorting Ocular Therapeutix?

Ocular Therapeutix saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,810,000 shares, an increase of 28.9% from the March 15th total of 9,160,000 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is currently 5.8 days. View Ocular Therapeutix's Short Interest .

When is Ocular Therapeutix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our OCUL earnings forecast .

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Monday, March, 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). The biopharmaceutical company had revenue of $14.80 million for the quarter, compared to analysts' expectations of $15.31 million. Ocular Therapeutix had a negative net margin of 138.15% and a negative trailing twelve-month return on equity of 321.12%.

What ETFs hold Ocular Therapeutix's stock?

ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD) , Northwest Biotherapeutics (NWBO) , Novavax (NVAX) , Dynavax Technologies (DVAX) , Omeros (OMER) , Gilead Sciences (GILD) , TG Therapeutics (TGTX) , Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX) .

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.59%). Insiders that own company stock include Antony C Mattessich , Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends .

How do I buy shares of Ocular Therapeutix?

Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OCUL

Ocular Therapeutix (OCUL) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free OCUL Stock Alerts

$6.01

-1.57 (-20.71%)

(As of 03:16 PM ET)

Compare

Today's Range: $6.00
▼
$7.61
50-Day Range: $5.03
▼
$10.93
52-Week Range: $2.00
▼
$11.31

Volume: 4.37 million shs
Average Volume: 1.99 million shs
Market Capitalization: $893.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.80

Get Ocular Therapeutix alerts:

Ocular Therapeutix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 167.1% Upside
$16.80 Price Target
Short Interest: Bearish
7.95% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.01
Upright™ Environmental Score
News Sentiment: 0.66
Based on 22 Articles This Week
Insider Trading: Acquiring Shares
$7 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.66 out of 5 stars

Medical Sector

246th out of 914 stocks

Pharmaceutical Preparations Industry

95th out of 415 stocks

3.5

Analyst's Opinion

Consensus Rating
Ocular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ocular Therapeutix has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.95% of the outstanding shares of Ocular Therapeutix have been sold short.
Short Interest Ratio / Days to Cover
Ocular Therapeutix has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Ocular Therapeutix has recently increased by 28.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Ocular Therapeutix does not currently pay a dividend.
Dividend Growth
Ocular Therapeutix does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Ocular Therapeutix has received a 57.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Ophthalmologicals (S01)" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Ocular Therapeutix is -2.01.

3.1

News and Social Media Coverage

News Sentiment
Ocular Therapeutix has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 22 news articles for Ocular Therapeutix this week, compared to 3 articles on an average week.
Search Interest
Only 16 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.
MarketBeat Follows
13 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ocular Therapeutix insiders have bought 3,492.29% more of their company's stock than they have sold. Specifically, they have bought $7,000,000.00 in company stock and sold $194,862.00 in company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Ocular Therapeutix is held by insiders.
Percentage Held by Institutions
59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Ocular Therapeutix are expected to remain at ($0.68) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ocular Therapeutix is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ocular Therapeutix is -5.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ocular Therapeutix has a P/B Ratio of 7.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

About Ocular Therapeutix Stock (NASDAQ:OCUL)

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OCUL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OCUL Stock News Headlines

April 18, 2024 | markets.businessinsider.com

Ocular Therapeutix Reports Positive Phase 1 Data For Axpaxli In NPDR

April 18, 2024 | seekingalpha.com

Ocular marks early-stage trial win for diabetic retinopathy candidate

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 18, 2024 | globenewswire.com

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

April 17, 2024 | theglobeandmail.com

April 17, 2024 | uk.investing.com

Ocular Therapeutix appoints new CEO amid leadership shift

April 17, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)

April 17, 2024 | americanbankingnews.com

Ocular Therapeutix (NASDAQ:OCUL) Given Market Outperform Rating at JMP Securities

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | markets.businessinsider.com

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts

April 16, 2024 | stockhouse.com

Ocular Therapeutix(TM) Strengthens Clinical Team with Appointment of Key Retinal Leaders

April 16, 2024 | finance.yahoo.com

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

April 16, 2024 | americanbankingnews.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Buy" from Analysts

April 15, 2024 | investorplace.com

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

April 15, 2024 | marketwatch.com

Ocular Therapeutix CEO Mattessich Steps Down, Executive Chairman Fills Role

April 15, 2024 | markets.businessinsider.com

Ocular Therapeutix CEO Mattessich To Step Down, Dugel To Succeed

April 15, 2024 | globenewswire.com

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

April 13, 2024 | msn.com

Remedies Recommended For Ocular Rosacea

April 9, 2024 | globenewswire.com

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

April 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Paxtrava’s Promising Efficacy and Safety Profile in Glaucoma Treatment

April 6, 2024 | globenewswire.com

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

April 1, 2024 | investorplace.com

Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential

March 26, 2024 | globenewswire.com

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

March 21, 2024 | finance.yahoo.com

Q4 2023 Clearside Biomedical Inc Earnings Call

March 19, 2024 | seekingalpha.com

Ocular Therapeutics' Impressive Surge: A Strategic Insight

March 17, 2024 | finance.yahoo.com

OCUL Apr 2024 12.500 put

March 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial Prospects

See More Headlines

Receive OCUL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:OCUL
CUSIP: N/A
CIK: 1393434
Web: www.ocutx.com
Phone: (781) 357-4000
Fax: 781-357-4001
Employees: 267
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.80
High Stock Price Target: $24.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +117.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-80,740,000.00
Net Margins: -138.15%
Pretax Margin: -138.15%
Return on Equity: -321.12%
Return on Assets: -53.93%

Debt

Debt-to-Equity Ratio: 0.82
Current Ratio: 6.66
Quick Ratio: 6.59

Sales & Book Value

Annual Sales: $58.44 million
Price / Sales: 19.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.79 per share
Price / Book: 9.76

Miscellaneous

Outstanding Shares: 148,630,000
Free Float: 140,453,000
Market Cap: $1.15 billion
Optionable: Optionable
Beta: 1.30

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Antony Mattessich (Age 56)
President, CEO & Director
Comp: $1.05M
Mr. Donald Notman Jr.
Chief Financial Officer
Dr. Jeffrey S. Heier M.D. (Age 63)
Chief Scientific Officer
Comp: $84.88k
Dr. Rabia Gurses Ozden M.D. (Age 55)
Chief Medical Officer
Comp: $621.39k
Dr. Pravin U. Dugel M.D. (Age 60)
Executive Chairman
Dr. Karen-Leigh Edwards M.B.A.
Ph.D., Chief Operations Officer
Dr. Peter K. Jarrett Ph.D. (Age 67)
Chief Technology Officer
Mr. Philip C. Strassburger Esq. (Age 64)
General Counsel
Comp: $282.61k
Mr. William H. Ransone II
Vice President of Global Sales & Marketing
Ms. Tracy Smith
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCUL Stock Analysis - Frequently Asked Questions

Should I buy or sell Ocular Therapeutix stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCUL shares.
View OCUL analyst ratings or view top-rated stocks.
What is Ocular Therapeutix's stock price target for 2024?: 5 brokers have issued 12-month target prices for Ocular Therapeutix's stock. Their OCUL share price targets range from $12.00 to $24.00. On average, they expect the company's share price to reach $16.80 in the next year. This suggests a possible upside of 167.1% from the stock's current price.
View analysts price targets for OCUL or view top-rated stocks among Wall Street analysts.
How have OCUL shares performed in 2024?: Ocular Therapeutix's stock was trading at $4.46 at the start of the year. Since then, OCUL shares have increased by 41.0% and is now trading at $6.29.
View the best growth stocks for 2024 here.
Are investors shorting Ocular Therapeutix?: Ocular Therapeutix saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,810,000 shares, an increase of 28.9% from the March 15th total of 9,160,000 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is currently 5.8 days.
View Ocular Therapeutix's Short Interest.
When is Ocular Therapeutix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our OCUL earnings forecast.
How were Ocular Therapeutix's earnings last quarter?: Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings data on Monday, March, 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). The biopharmaceutical company had revenue of $14.80 million for the quarter, compared to analysts' expectations of $15.31 million. Ocular Therapeutix had a negative net margin of 138.15% and a negative trailing twelve-month return on equity of 321.12%.

What ETFs hold Ocular Therapeutix's stock?: ETFs with the largest weight of Ocular Therapeutix (NASDAQ:OCUL) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
What other stocks do shareholders of Ocular Therapeutix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).
Who are Ocular Therapeutix's major shareholders?: Ocular Therapeutix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (1.59%). Insiders that own company stock include Antony C Mattessich, Christopher G White, Donald Notman, Philip C Strassburger, Rabia Gurses Ozden, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends.
How do I buy shares of Ocular Therapeutix?: Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCUL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial